DNA Replication (I)

1. DNA Replication (I) 王之仰

2. Any eukaryotic chromosome contain three functional elements to replicate and segregate correctly: (1) replication origins at which DNA polymerases and other proteins initiate synthesis of DNA; (2) the centromere, the constricted

5. region required for proper segregation of daughter chromosomes; and (3) the two ends, or telomerases. • Replication of DNA begins from sites that are scattered throughout enkaryotic chromosomes.

6. The yeast genome contains many ~100 bp sequences, called autonomously replicating sequences (ARSs), that act as replication origins. • Up to 20% of progeny cells are faulty on the mitotic segregation.

10. A CEN sequence (yeast centromere sequence) leads to a equal or nearly equal segregation of yeasts during mitosis. • If circular plasmids containing an ARS and CEN sequence are cut, the resulting linear plasmids do not replicate unless they contain

11. special telomeric (TEL) sequences ligated to their ends. • Three regions (I, II, and III) of the centromere are conserved among different chromosomes. • Conserved sequences are present in the region I and III.

12. ; the region II has a fairly constant length (rich in A and T residues) and it contains no definite consensus sequences. • Regions I and III are bound by proteins that interact with more than 30 proteins.

14. which in turn bind to microtubules. • Region II is bound to a nucleosome that has a variant form of histone H3 replacing the usual H3. • Centromeres from all eukaryotes similarly are bound by nucleosomes

15. with this specialized, centromere-specific form of histone H3, called CENP-A. • In human, centromeres contain 2- to 4-megabase arrays of a 171-bp simple-sequence DNA called alphoid DNA.

17. The telomere repeat sequence in vertebrates is TTAGGG; these simple sequences are repeated at the very termini of chromosomes. • The 3’end of the G-rich strand extends 12-16 nucleotides beyond the 5’-end of the complementary C-rich strand; The region is bound

18. by specific proteins that protect the ends of linear chromosomes from attacked by exonucleases. • The need for a specialized region at the ends of eukaryotic chromosome is apparent when we consider all DNA polymerases elongate DNA chain at the 3’-end, all require an

19. RNA or DNA primer. • Unlike the leading strand, the lagging-strand template is copied in a discontinuous fashion, it cannot be replicated in its entirety. • The telomere shortening is solved by an enzyme that adds telomeric (TEL) sequences to the ends of each

20. chromosome. • Because the sequence of the telomerase-associated RNA serves as the template for addition of dNTPs to the ends of telomeres-the

21. source of the enzyme and not the source of the telomeric DNA primer determines the sequence added. • Telomerase is a specialized form of a reverse transcriptase that carries its own internal RNA template to direct DNA synthesis.

25. The human genes expressing the telomerase protein and the telomerase-associated RNA are active in germ and stem cells, but are nearly turned off in most cells of adult cells. • These genes are activated in most cancer cells, where telomerase is

26. required for the multiple cell divisions necessary to form a tumor. • Telomerase prevents telomere shortening in most eukaryotes, some organisms use alternative strategies; Drosophila species maintain telomere lengths by the regulation insertion of non-LTR

27. retrotransposons into telomeres. • Telomeres: the physical ends of linear chromosomes, consist of tandem arrays of a short DNA sequence, TTAGGG in vertebrates. Telomeres provide the solution to the end-replication problem-the inability of DNA polymerases to

29. completely replicate the end of a double-stranded DNA molecule. • Embryonic cells, germ-line cells, and stem cells produce telomerase, but most human somatic cells produce only a low level of telomerase as they enter S phase;

30. their telomeres shorten with each cell cycle. • Complete loss of telomeres leads to end-to-end chromosome fusions and cell death. • Extensive shortening of telomeres is recognized by the cell as a kind of DNA damage, with consequent

31. stabilization and activation of p53 protein, leading to p53-triggered apoptosis. • Most tumor cells, despite their rapid proliferation rate, overcome this fate by producing telomerase. • Specific inhibitors of telomerase have been used as a cancer therapeutic

33. agents. • Introduction of telomerase-producing transgenes into cultured human cells can extend their lifespan by more than 20 doublings while maintaining telomere length. • Treating human tumor cells with anti-sense RNA against telomerase

34. caused them to cease growth in about four weeks. • Dominant-negative telomerases, such as those carrying a modified RNA template, can interfere with cancer cell growth-when such a mutant was expressed in prostate or breast cancer cells, the cells became apoptotic.

35. Genetic approaches have demonstrated that mice homozygous for a deletion of the RNA subunit of telomerase are viable and fertile was surprising. However, after four to six generations defects began to appear in the telomerase-null mice as their very long telomeres (40-60

36. kb) became significantly shorter; the defects included depletion of tissues that require high rates of cell division, like skin and intestine, and infertility. • Skin papilloma induced by a combination of chemical carcinogens occurs 20 times less

37. frequently in mice lacking a functional telomerase than in normal mice, presumably because p53-triggered apoptosis is induced in response to the ever shortening telomeres of cells that have begun to divide. • If both telomerase and p53 are absent, there is an increased rate of epithelial

38. tumors such as squamous-cell carcinoma, colon, and breast cancer. • Mice with an APC mutation normally develop colon tumors, and these too are reduced if the mice lack telomerase.